<DOC>
	<DOCNO>NCT01659814</DOCNO>
	<brief_summary>The overall aim study utilize integrative research model order dynamically assess reward-related dopamine ( DA ) transmission major depressive disorder ( MDD ) test role dysfunctional DA release depression anhedonia . The first arm line research ( PET scan ) aim investigate phasic DA release MDD incentive motivation . The investigator utilize establish molecular imaging technique measure striatal DA release dynamically performance test control version monetary incentive delay task , involve anticipation receipt monetary reward . In , experiment link together independent line research associate depression decrease hedonic responsiveness , impaired reinforcement learn dysfunctional DA transmission . We hypothesize , relative matched control , unmedicated MDD subject show reduce reward-related ligand ( 11C-raclopride ) displacement . Reduced ligand displacement interpret indicate reduce task-induced release endogenous striatal DA response reward-predicting cue unpredictable reward MDD subject . In second arm research ( EEG record ) , investigator aim probe spatio-temporal dynamic brain mechanism underlie positive negative reinforcement learn MDD relation phasic DA . Participants perform probabilistic stimulus selection task ( PSST ) event-related potential ( ERPs ) collect . The investigator expect , relative matched control , unmedicated MDD subject show reduce positive reinforcement learning , potentiate negative reinforcement learning , large ( i.e. , negative ) feedback-related negativity ( FRN ) response positive reinforcement ( indicative reduce DA transmission ) . Moreover , investigator hypothesize negative FRN response positive reinforcement associate decreased striatal raclopride displacement ( i.e. , low release endogenous DA ) measure PET first part study . This experiment investigate effect blunt DA transmission behavioral ERP marker positive negative reinforcement learning .</brief_summary>
	<brief_title>Dopamine Neurotransmission Major Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Anhedonia</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Both gender ethnic origin , age 18 45 ; Written inform consent ; Righthanded ( Chapman Chapman 1987 ) ; Absence serious unstable medical illness , include cardiovascular , hepatic , renal , respiratory , endocrine , neurologic hematologic disease ; Absence history seizure disorder ; Absence history current diagnosis follow DSMIV psychiatric illness : organic mental disorder , schizophrenia , schizoaffective disorder , delusional disorder , psychotic disorder otherwise specify , bipolar disorder , patient mood congruent mood incongruent psychotic feature , substance dependence , substance abuse within last 12 month ( exception cocaine stimulant abuse ; lead exclusion ) , assess subject history structure clinical interview ( SCIDI/NP ) ; Absence history cocaine stimulant use ( e.g. , amphetamine , cocaine , methamphetamine ) ; Absence history use dopaminergic drug ( include methylphenidate ) ; Absence current use psychotropic drug Absence substance dependence substance abuse last 12 month ; Absence history current diagnosis dementia , score great 26 Mini Mental Status Examination ( Folstein , 1975 ) screen visit ; Absence clinical laboratory evidence hypothyroidism ; Absence neurological illness Specific exclusion criterion PET scan follow : Pregnant woman , woman try get pregnant , woman childbearing potential use medically accept mean contraception ( define implant , condom , diaphragm , spermicide , IUD , s/p tubal ligation , partner vasectomy ) . Failure meet standard PET safety requirement . Specific inclusion criterion depress participant follow : DSMIV diagnostic criterion MDD melancholia subtype ( diagnose use SCID ) MDD anhedonia ( score 3 great SnaithHamilton Pleasure Scale ( SHPS ) ) ; A baseline HRSD score ( Hamilton 1960 ) great equal 16 ( 17item version ) ; Absence suicidal ideation outpatient treatment determine unsafe study clinician . These patient immediately refer appropriate clinical treatment ; Absence past current mood congruent incongruent psychotic feature ; Absence lifetime history electroconvulsive therapy ( ECT ) Subjects take antidepressant time screen visit enrol willing ( discuss prescribe clinician ) , study clinician determines clinically appropriate discontinue current antidepressant period great five halflives current medication ( long 7 day ) . For subject , baseline visit first physiology session occur 7 day interval pass . Specific inclusion criterion control participant follow : Absence psychiatric illness ( include alcohol substance abuse ) , assess subject history structure clinical interview ( SCIDI/NP ) . Absence medication least three week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Anhedonia</keyword>
	<keyword>Dopamine</keyword>
	<keyword>Electroencephalography ( EEG )</keyword>
	<keyword>Positron Emission Tomography ( PET )</keyword>
	<keyword>Reward</keyword>
</DOC>